AzTrials
AzTrials

NSCLC Stage IVPhase 2IMMUNOSABR2NCT03705403

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

A Phase 2 study testing Darleukin and Radiation in people with NSCLC Stage IV and Metastatic Disease, run by Maastricht University Medical Center at 15 sites in 6 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
NSCLC Stage IV, Metastatic Disease
What is being tested?
Darleukin and Radiation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
88 participants
Where
15 sitesin 6 countries
Study dates
4 Apr 2019to 6 Jan 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Oligometastatic disease (≤5 metastases)
  • Histological confirmed limited metastatic adult NSCLC patients, regardless of the PD-L1 status.
  • Maximum of 5 metastatic lesions, maximum two brain lesion with a total cumulative diameter of 5cm is allowed.
  • SOC baseline imaging e.g MRI and/or PET-CT and CT-brain or MRI brain and/or CT-scan with at least covering thorax-upper abdomen-brain, within 6 weeks prior to randomisation.
  • If a patient has unclear lesions in the liver or brain an MRI would be advised following the ESMO guidelines.
  • o In patients with 2 lung tumours, it can be unclear if the patient has 2 concurrent primary tumours or a primary lung tumour with 1 metastasis. In this case, the local multidisciplinary tumour board will decide whether the patient has an M1 disease or not.
Show all 36Show fewer
  • Previous treatment: Prior cancer treatments are allowed but must be discontinued for at least 4 weeks before randomisation. In case of maintenance chemotherapy, this therapy will only be started after the end of the L19-IL2 treatment or only in case of Anti-PD(L)1 treatment, during L19-IL2 therapy.
  • Age of 18 years or older.
  • WHO performance status 0-1;
  • Adequate bone marrow function, evaluated in the local laboratory (Lab): Absolute Neutrophil Count (ANC) of ≥ 1.0 x 109 /L, platelet count ≥ 100 x 109/L, Haemoglobin (Hb) ≥ 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low);
  • Adequate hepatic function (evaluated in the local lab): total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase ≤ 2.5 x ULN for the institution or ≤ 5 in case of liver metastasis);
  • Adequate renal function (evaluated in the local lab): creatinine clearance of at least 40 ml/min;
  • Adequate endocrine (TSH, FT4) function, local guidelines
  • The patient is capable of complying with study procedures;
  • Life expectancy of at least 12 weeks;
  • Negative serum pregnancy test for females of childbearing potential.
  • Signed and dated written informed consent.
  • Ability to comply with contraception requirements:
  • Non-sterilised, sexually active male patient with a female partner who is of child-bearing age, must use two acceptable birth control methods like a condom combined with spermicidal cream or gel from the first dose of study medicine, during the study and at least up to 12 weeks after the last administration of the study medicine and up to 5 months after the last dose of the medicine with anti-PDL)1 as an action mechanism (if you get this product besides the study medicine), as an addition to the use, by the female partner, of as described in the following section:
  • Women of childbearing potential (WOCBP) and WOCBP partners of male patients must be using, from the screening to three months following the last study drug administration and 4 5 months after last dose of anti-PD(L)1 maintenance treatment, effective contraception methods ((a) IUD (IUD) or intrauterine hormone delivery system (IUS), b) combined (with estrogen and progesterone) hormonal contraception associated with ovulation inhibition (oral, intravaginal, transdermal), c) hormonal contraception with progesterone only associated with ovulation inhibition (oral, injectable, implantable), as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html).
  • Poly-metastatic disease (6 to 10 metastases)
  • Histological confirmed limited metastatic adult NSCLC patients, regardless of the PD-L1 status.
  • A minimum of 6 and maximum of 10 metastatic lesions, maximum two brain lesion with a total cumulative diameter of 5cm is allowed.
  • At least one measurable lesion (according to RECIST 1.1) that has no overlap with the PTV of the lesion subjected to radiotherapy.
  • Previous treatment: The time between the last administration of chemotherapy and the randomisation must be at least 4 weeks. In case of maintenance chemotherapy, this therapy will only be started after the study if e-arm, allowed during c-arm. In case of Anti-PD(L)1 treatment, this is allowed in both arms, so also during L19-IL2 therapy.
  • Age of 18 years or older;
  • WHO performance status 0-1;
  • Adequate bone marrow function (evaluated in the local lab): Absolute Neutrophil Count (ANC) of ≥ 1.0 x 109 /L, platelet count ≥ 100 x 109/L, Hb ≥ 6.0 mmol/L (or 9.67 g/dL) (it is allowed to give a blood transfusion if Hb is initially too low);
  • Adequate hepatic function (evaluated in the local lab): total bilirubin ≤ 1.5 x upper limit of normal (ULN) for the institution; ALT, AST, and alkaline phosphatase ≤ 2.5 x ULN for the institution or ≤ 5 in case of liver metastasis);
  • Adequate renal function (evaluated in the local lab): creatinine clearance of at least 40 ml/min;
  • Adequate endocrine (TSH, FT4) function, local guidelines;
  • The patient is capable of complying with study procedures;
  • Life expectancy of at least 12 weeks;
  • Negative serum pregnancy test for females of childbearing potential;
  • Ability to comply with contraception requirements (see oligo)
  • Signed and dated written informed consent.

Who cannot join

  • More than 10 metastatic lesions.
  • More than 2 brain metastatic lesions.
  • 2 brain metastases with a cumulative diameter larger than 5 cm.
  • Patients with non-infectious pneumonitis, uncontrolled thyroid disease, pleuritis, pericarditis and peritonitis carcinomatosis.
  • Patients who received live vaccines 30 days or fewer prior to enrolment.
  • Patients who are already actively participating in another study.
Show all 24Show fewer
  • Patients who need simultaneous radiation on the primary tumour and metastatic lesion(s). For these patients it might be an option to treat the primary tumour first although this is not mandatory for this study. There must be minimal four weeks between last treatment and randomisation.
  • Whole brain radiotherapy (WBRT) is not allowed, although it is accepted when given at least 4 weeks prior to randomisation or after the treatment period. Patients with stable brain metastases are not excluded.
  • Previous radiotherapy to an area that would be re-treated by (SAB)R, resulting in overlap of the high dose areas.
  • Maintenance therapy with Anti-PD(L)1 treatment combined with chemotherapy is not allowed during treatment ((SAB)R and L19-IL2 cycles).
  • Other active malignancy or malignancy within the last 2 years (except localised skin basal/squamous cell carcinoma, non-muscle invasive carcinoma of the bladder or in situ carcinoma from any site).
  • Concomitantly administered glucocorticoids may decrease the activity of IL2 and therefore should be avoided. However, patients who develop life-threatening signs or symptoms may be treated with dexamethasone until toxicity resolves or reduces to an acceptable level (generally grade 1 and 2, however must be based at the research physician's discretion).
  • History of allergy to intravenously administered proteins/peptides/antibodies/ radiographic contrast media.
  • HIV positive; active HIV infection, or active hepatitis B or C (assessed in local lab).
  • Systemic treatment with either corticosteroid (>10 mg daily prednisone equivalents) or Interferon alpha or immunosuppressive medications within 14 days prior to randomisation. Topical or inhalation steroids are allowed. If a patient needs to take unexpectedly immunosuppressive medication during the trial, it will be allowed but decreasing the dose as soon as possible is strongly advised.
  • Prior history of organ transplant, including autologous stem cell transplant.
  • Acute or sub-acute coronary syndromes within the last year, acute inflammatory heart disease, heart insufficiency NYHA > 2, or irreversible cardiac arrhythmias.
  • A known impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO.
  • Uncontrolled hypertensive disease; (systolic blood pressure (SBP) ≥160 or diastolic blood pressure (DBP) ≥100 mm Hg during two measurements).
  • History or evidence of active autoimmune disease.
  • Severe diabetic retinopathy (neoangiogenesis targeted by L19 outside the tumour).
  • Major trauma, including oncologic surgery, but excluding smaller procedures like the placement of porth-à-cath or surgical biopsy, within 4 weeks prior to randomisation (neoangiogenesis targeted by L19 outside a tumour).
  • Any underlying mental, medical or psychiatric condition which in the opinion of the investigator will make administration of study drug hazardous or hinder the interpretation of study results. Unstable or serious concurrent uncontrolled medical conditions.
  • Pregnancy or breast feeding; it is well known that ED-B, the target of both L19IL2, is expressed in a variety of fetal tissues. Furthermore, anti-PD(L)1 treatment may increase the risk of immune-mediated disorders. Therefore, it will be contra-indicated for pregnant or lactating women.

Trial locations and contacts

15 sites in 6 countries.

15 sites in 6 countries

Belgium4 sites

  • UCL St. Luc

    Brussels

  • UZ Gent

    Ghent

  • UZ Leuven

    Leuven

  • GZA Ziekenhuizen campus Sint-Augustinus

    Wilrijk

Other trials in Belgium

Netherlands4 sites

  • AVL-NKI

    Amsterdam

  • Academisch Ziekenhuis Maastricht (Leading Centre)

    Maastricht, Limburg, 6229HX

  • Radboud UMC Nijmegen

    Nijmegen

  • Erasmus MC

    Rotterdam

Other trials in Netherlands

Germany3 sites

  • University Hospital Carl Gustav Carus

    Dresden

  • Klinikum der Universität Heidelberg

    Heidelberg

  • University Hospital Tübingen

    Tübingen

Other trials in Germany

France2 sites

  • Centre Oscar Lambret Lille

    Lille

  • INSTITUT régional du CANCER MONTPELLIER - ICM - VAL d'AURELLE

    Montpellier

Other trials in France

Italy1 site

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore

    Rome

Other trials in Italy

United Kingdom1 site

  • University College London Hospital

    London

Other trials in United Kingdom

About this study

Official title: Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial

This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with two arms; C-arm and an E-arm.

Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10) will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be given after irradiation.

Read the detailed description

IMMUNOSABR will include 126 patients. In this single-stage controlled randomised open-label phase II trial, we aim to demonstrate an absolute increase in progression-free survival (primary endpoint). PFS will be determined as the time between randomisation and disease progression, according to RECIST 1.1, death due to any cause or last patient contact alive and progression-free. Patients will be randomized between control (no immunocytokine) and experimental arms (with immunocytokine L19-IL2) in a 1:1 ratio. The accrual period will be 29 months (or 2.41 years), and the minimum follow-up will be 18 months (or 1.5 years), making the total study duration 47 months. Comparison between control and experimental arms will be made using the Log-Rank statistic. This test for superiority will be one-sided with the desired type I error of 0.10 and power of 0.90.

Patients enrolled in the trial will be randomised into the control arm (C-arm) or experimental arm (E-arm).

  • C-arm: Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiotherapy and/or SABR, oligometastatic disease.
  • E-arm: SABR (oligometastatic disease) or radiotherapy (diffuse disease) + L19-IL2 up to 6 cycles (+ aPD(L)1 if SOC)

The expected 1.5-year PFS is 15% in the C-arm and 35% in the E-arm. A sample size of 116 patients (58 patients per treatment arm) is needed to show this difference of 20% in PFS, using a logrank test with a two-sided alpha of 0.05 and power of 85%. Patients will be evenly divided over the two arms. Assuming a drop-out rate of 10%, a total of 126 patients (63 per arm) need to be included.

Primary objective The main objective of the trial is to test if the activity of the combination of (SAB)R and L19-IL2 in patients with metastatic NSCLC will result in improved progression-free survival (PFS) compared to the SOC.

Secondary Objectives

  • Assessment of the PFS of the patient cohort, at 5 years after randomisation.
  • Assessment of the overall survival of the patient cohort, at 5 years after randomisation.
  • To assess the toxicity of this treatment schedule;
  • To assess Quality of Life (QoL);
  • To assess the occurrence of an Out of Field Radio-Immune (OFRI) response / abscopal effect using imaging;
  • To assess the occurrence of an In Field Radio-Immune (IFRI) response using imaging;
  • To perform correlative biomarker studies related to treatment response.

Exploratory endpoints:

  • Correlative biomarker studies:
  • Tumour tissue: e.g EDB expression, non-synonymous mutations, immune monitoring;
  • Blood: e.g. EDB expression, cfDNA, and immune monitoring;
  • Radiomics on CT and if available MRI;
  • Faeces: diversity in microbiota.
  • iRECIST
  • Tumour grow kinetics
Being tested
Darleukin, Radiation
Medical subject headings
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DarleukinDrug

    Also called L19 - IL2

    The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.

  • RadiationRadiation

    Also called Radiotherapy

    Radiotherapy

Study groups in NCT03705403
Study groupRoleWhat they receive
ControlActive comparatorStandard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
Receives: Radiation: Radiation
Experimental treatmentExperimentalStandard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
Receives: Drug: Darleukin; Radiation: Radiation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free survival

    The main objective of the trial is to test the hypothesis that the combination of (SAB)R and L19-IL2 in patients with metastatic NSCLC will resulting in improved progression-free survival (PFS) compared to the SOC.

    Measured: 18 months after randomization of the last patient

Secondary outcomes (7)

  1. Overall survival

    Assesment of the overall survival of the patient cohort.

    Measured: 18 months after randomization of the last patient

  2. Change in score of The EORTC quality of life questionnaire (QLQ) core module (C30)

    The EORTC QLQ assesses health-related QoL of cancer patients; it consists of 30 items and covers 9 domains + 6 single symptoms. There are 5 functional scales: physical, role functioning, cognitive, emotional, social; 3 symptom scales: fatigue, pain, nausea + vomiting; a global health and QoL scale, and 6 single items. Each item has four response alternatives: 1) not at all, 2) a little 3) quite a bit 4) very much (score 1-4 with range 3); except for the global health-status/quality of life scale, which has options ranging from 1) very poor to 7) excellent (score 1-7, range 6). Answers are combined into dimensions and scores are linearly transformed into a score of 0 to 100 according to the scoring manual of the EORTC QoL group. For functional and global QoL scales, higher scores mean better level of functioning. For symptom-oriented scales, a higher score means more severe symptoms. Scores are reported as mean and standard deviation. Scores will be used in multilevel-analysis.

    Measured: baseline and at 3, 6, 9, 12, 15, 18, 21, 24 months after treatment

  3. Change in score of The EORTC quality of life questionnaire (QLQ) - Lung cancer module (LC13)

    The EORTC QLQ-LC13 The Lung Cancer Module is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30. The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis. All items are scored 1 to 4, giving range = 3. After linear transformation scores range from 0 to100. A high score represents a high level of symptomatology or problems.

    Measured: baseline and at 3, 6, 9, 12, 15, 18, 21, 24 months after treatment

  4. Change in score of The Euro Quality of Life - 5 dimensions - 5 levels (EQ-5D-5L)

    EQ-5D-5L is a standardized instrument developed by the EuroQol Group as a measure of general health-related quality of life that can be used in a wide range of health conditions and treatments. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems (score 1-5). The scores for the five dimensions are combined into a 5-digit number that describes the patient's health state.

    Measured: baseline and at 3, 6, 9, 12, 15, 18, 21, 24 months after treatment

  5. Change in score of The Euro Quality of Life (EQ) visual analogue scale (VAS)

    The EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0-100. This can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

    Measured: baseline and at 3, 6, 9, 12, 15, 18, 21, 24 months after treatment

  6. Change in out of field radio-immune (OFRI) response

    To assess the occurrence of an out of field radio-immune (OFRI) response, with a scan. Assessment will be based on the RECIST criteria.

    Measured: at 3, 6, 9, 12, 15, 18, 21, 24 months after treatment

  7. Immunoresponse blood biomarkers by enzyme-linked immunosorbent assay (ELISA)

    To perform correlative biomarker studies related to treatment response immunoresponse blood biomarkers will be measured: osteopontin (OPN), carbonic anhydrase IX (CA-IX)], interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP), carcinoembryonic antigen (CEA), cytokeratin fragment 21-1 (Cyfra 21-1), alpha-2-macroglobulin (α2M), serum interleukin-2 receptor (sIL2r), toll-like receptor 4 (TLR4), vascular endothelial growth factor (VEGF), extradomain-B fibronectin (EDB). This part of the study is exploratory.

    Measured: baseline and at 3, 6 and 9 months after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2018
  2. Study start4 Apr 2019
  3. Primary completion6 Jan 2025
  4. Study completion6 Jan 2025

Why it stopped: This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This will be a multicentre, randomised controlled open-label phase II trial testing if the combination of (SAB)R and immunocytokine L19-IL2 improves the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The patients included in the trial will be stratified for the metastatic load (oligo; max 5 or diffuse; 6-10 metastases). After randomisation, patients will be assigned either to the experimental arm or the standard of care (SOC) arm. Depending on the metastatic load, patients with (max 5 metastases) will receive in the experimental arm SABR to all lesions followed by L19-IL2 followed by standard of care therapy. Patients with more extensive metastatic disease (6 to up to 10 metastasis) in the experimental arm will be included following first or second line treatment with a platinum doublet and receive radiotherapy (3x8 Gy) to at least one (symptomatic) lesion, followed by L19-IL2 followed by SOC.
Masking
None (open label)
Enrolment
88 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03705403
Sponsor's protocol ID
UM2018IMMUNOSABR2RLPL
Acronym
IMMUNOSABR2
Status last verified
Jan 2025
First submitted
27 Jun 2018
Last updated
30 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Olivo Pimentel V, Marcus D, van der Wiel AM, Lieuwes NG, Biemans R, Lieverse RI, Neri D, Theys J, Yaromina A, Dubois LJ, Lambin P. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. J Immunother Cancer. 2021 Mar;9(3):e001764. doi: 10.1136/jitc-2020-001764.

    PubMed 33688020

  • Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruysscher D, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer. 2020 Jun 15;20(1):557. doi: 10.1186/s12885-020-07055-1.

    PubMed 32539805

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Darleukin and Radiation in people with NSCLC Stage IV and Metastatic Disease, run by Maastricht University Medical Center at 15 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 36 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Belgium, Netherlands, Germany, France, Italy and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free survival (time frame: 18 months after randomization of the last patient). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03705403, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in